RECOMMENDATION FOR THE TREATMENT OF LATENT TUBERCULOSIS INFECTION
Recently revised recommendations for the treatment of latent tuberculosis infection (LTBI) include new thera-peutic regimens as follows:
Isoniazid for 9 months daily or twice weekly is preferred for all adults.
Isoniazid for 6 months daily or twice weekly is ac-ceptable for HIV-negative patients and is cost effective.
Rifampin and pyrazinamide daily for 2 months is appropriate for isoniazid-resistant tuberculosis.
Rifampin daily for 4 months may be given to indi-viduals who cannot tolerate pyrazinamide.